{"search_session":{},"preferences":{"l":"es","queryLanguage":"es"},"patentId":"091-653-740-898-426","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"091-653-740-898-426"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8901,"type":"PATENT","title":"University of Michigan Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":14369,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8216,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners= \"Univ Michigan\", \" Michigan Univ\", \" Univ Michigan NOT state NOT tech NOT Eastern\", \"Univ Michigan NOT technological\", \" Univ Michigan NOT Western\"
Select more for logical variants
Add to collection
Total patent : 14104
Search Applicants and Owners= \"Univ Michigan\", \" Michigan Univ\", \" Univ Michigan NOT state NOT tech NOT Eastern\", \"Univ Michigan NOT technological\", \" Univ Michigan NOT Western\"
Select more for logical variants
Add to collection
Total patent : 14104
wherein\n
k, l, and o are independently 0, 1, 2, 3, 4, 5, or 6;\n
W is C or N;\n
X1, X2, X3, X4, and X5 are independently selected from the group consisting of —H, —OH, —OR, —F, —Cl, —Br, —I, —NO2, —NO, —N(R)2, —N(R)3+, —C(O)R,—C(O)OR, —CHO, —C(O)NH2, —C(O)SR, —CN, —S(O)2R, —SO3R, —SO3H, —SO2N(R)2, —S═O, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;\n
Y1 is selected from the group consisting of O, NH, NRa, S, and CH2;\n
Y2 is selected from the group consisting of O, NH, NRb, S, and CH2;\n
R, Ra, and Rb are independently selected from the group consisting of C1 to C6 alkyl, C3 to C6 cycloalkyl, CH2—C3-C6 cycloalkyl, phenyl, tolyl, and benzyl;\n
Z1 and Z2 are independently selected from the group consisting of C, P—OH, S, and S═O;\n
U is selected from the group consisting of —NRcC(O)ORe, —NRcC(O)NRfRe, —NRcC(O)SRe, —NRcP(O)(OH)Re, —NRcP(O)(OH)ORe, —NRcP(O)(OH)NRfRe, —NRcP(O)(OH)SRe, —NRcS(O)Re, —NRcS(O)ORe, —NRcS(O)NRfRe, NRcS(O)SRe, —NRcS(O)2Re, —NRcS(O)2ORe, NRcS(O)2NRfRe, —NRcS(O)2SRe, —OC(O)ORe, —OC(O)NRfRe, —OC(O)SRe, —OP(O)(OH)Re, —OP(O)(OH)ORe, —OP(O)(OH)NRdRe, —OP(O)(OH)SRe, —OS(O)Re, —OS(O)ORe, —OS(O)NRdRe, —OS(O)SRe, —OS(O)2Re, —OS(O)2ORe, —OS(O)2NRdRe, —OS(O)2SR, and —C(O)Rc;\n
Rc and Rd are independently selected from the group consisting of H, C1 to C12 alkyl, C1 to C12 haloalkyl, C3 to C6 cycloalkyl, (CH2)m—C3-C6 cycloalkyl, C2 to C6 heterocycloalkyl, (CH2)m—C2-C6 heterocycloalkyl, benzyl, aryl, (CH2)m-aryl, heteroaryl, (CH2)m-heteroaryl, and substituted derivatives thereof, or Rc and Rd taken together with the N atom to which they are bonded form a 3- to 8-membered heterocyclic ring;\n
m is 1, 2, 3, 4, 5, or 6;\n
Rf is selected from the group consisting of H, C1 to C12 alkyl, C1 to C12 haloalkyl, C3 to C6 cycloalkyl, (CH2)m—C3-C6 cycloalkyl, C2 to C6 heterocycloalkyl, (CH2)m—C2-C6 heterocycloalkyl, benzyl, aryl, (CH2)m-aryl, heteroaryl, (CH2)m-heteroaryl, and substituted derivatives thereof; and\n
Re is selected from the group consisting of H, C1 to C12 alkyl, C1 to C12 haloalkyl, C3 to C6 cycloalkyl, (CH2)m—C3-C6 cycloalkyl, C2 to C6 heterocycloalkyl, (CH2)m—C2-C6 heterocycloalkyl, benzyl, aryl, (CH2)m-aryl, heteroaryl, (CH2)m-heteroaryl,\n\n
and substituted derivatives thereof."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 1 having a formula LXIII, or a salt, ester, or prodrug thereof:\n
wherein k, l, o, W, X1, X2, X3, X4, Y1, Y2, Z1, Z2, and U are as defined in claim 1."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 1 or a salt, ester, or prodrug thereof, wherein Re is substituted aryl having a formula:\n
X5 and X6 are independently selected from the group consisting of —H, —OH, —OR, —F, —Cl, —Br, —I, —NO2, —NO, —N(R)2, —N(R)3±, —C(O)R, —C(O)OR, —CHO, —C(O)NH2, —C(O)SR, —CN, —S(O)2R, —SO3R, —SO3H, —SO2N(R)2, —S═O, aryl, substituted aryl, and heteroaryl; and\n
R is selected from the group consisting of C1 to C6 alkyl, C3 to C6 cycloalkyl, CH2—C3-C6 cycloalkyl, phenyl, tolyl, and benzyl."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 1 or a salt, ester, or prodrug thereof, wherein Re is selected from the group consisting of 4-chlorophenyl, 4-fluorophenyl, 2,5-dihydroxyphenyl, 2,5-dimethoxyphenyl, 3-(trifluoromethyl)phenyl, 4-chloro-2-fluorophenyl, 2,4-dihydroxyphenyl, 2,4-dimethoxyphenyl, 3,5-dichloro-4-hydroxyphenyl, 3,5-difluoro-4-hydroxyphenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 3,5-dichloro-4-methoxyphenyl, 3,5-difluoro-4-methoxyphenyl, 4-methylphenyl, phenyl, naphthyl, biphenyl, indolyl, methyl, 2-chlorophenyl, (1-trichloromethyl-1-methyl)ethyl, 1,1-dimethylethyl, 2,2-dimethylpropyl, benzyl, (2-pyridinyl)methyl, (3-pyridinyl)methyl, (4-pyridinyl)methyl, and"],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 1 having a formula XCI or a salt, ester, or prodrug thereof:\n
wherein Re is selected from the group consisting of 4-chlorophenyl, 4-fluorophenyl, 2,5-dihydroxyphenyl, 2,5-dimethoxyphenyl, 3-(trifluoromethyl)phenyl, 4-chloro-2-fluorophenyl, 2,4-dihydroxyphenyl, 2,4-dimethoxyphenyl, 3,5-dichloro-4-hydroxyphenyl, 3,5-difluoro-4-hydroxyphenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 3,5-dichloro-4-methoxyphenyl, 3,5-difluoro-4-methoxyphenyl, 4-methylphenyl, phenyl, and methyl."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 1 having a formula XCII or a salt, ester, or prodrug thereof:\n
wherein Re is selected from the group consisting of phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, (1-trichloromethyl-l-methyl)ethyl, 3-(trifluoromethyl)phenyl, 2,2-dimethylpropyl, benzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 2-bromobenzyl, 3-bromobenzyl, 4-bromobenzyl, 2-iodobenzyl, 3-iodobenzyl, 4-iodobenzyl, (2-pyridinyl)methyl, (3-pyridinyl)methyl, (4-pyridinyl) methyl, C1 to C6 alkyl, and"],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 1, wherein Rc, Rd, and Rf are independently selected from the group consisting of phenyl, tolyl, naphthyl, biphenyl, and indolyl."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 1 having a formula CL or a salt, ester, or prodrug thereof:\n
wherein X1 and X3 are independently selected from the group consisting of —H and —OH; U is selected from the group consisting of —NHC(O)ORe and —NHC(O)NHRe; and Re is selected from the group consisting of 1-naphthyl, 2-naphthyl, 4-biphenyl-1-yl, and substituted derivatives thereof."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A compound having a formula selected from the group consisting of LXIV, LXXXI, LXXXVI, LXXXIX, XC, C, CIII, CIV, CXII, CXIII, CXIV, CXIX, CXX, CXXI, CXXXV, CXXXVI, CXXXVII, CXXXVIII, CXXXIX, CLX, CLXI, and salts, esters, or prodrugs thereof:"],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 1 or a salt, ester, or prodrug thereof, wherein U is —NRcC(O)ORe."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A composition comprising the compound according to claim 1 or a salt, ester, or prodrug thereof and a pharmaceutically acceptable carrier."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A method of increasing circulating high density lipoprotein (HDL) in a subject, comprising administering to said subject a plasminogen activator inhibitor-1 (PAI-1) inhibitor compound according to claim 1 in an amount effective to increase HDL."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A method of decreasing circulating very low density lipoprotein (VLDL) in a subject, comprising administering to said subject a plasminogen activator inhibitor-1 (PAI-1) inhibitor compound according to claim 1 in an amount effective to decrease VLDL."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12 or 13, wherein the subject is human."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12 or 13, wherein the PAI-1 inhibitor decreases PAI-1 binding to apolipoprotein E (ApoE)."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12 or 13, wherein the PAI-1 inhibitor decreases PAI-1 binding to apolipoprotein A (ApoA)."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12 or 13, wherein the PAI-1 inhibitor decreases PAI-1 binding to VLDL."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12 or 13, wherein the PAI-1 inhibitor binds to PAI-1 in the presence of vitronectin."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12 or 13, wherein the PAI-1 inhibitor binds to PAI-1 in the presence of urokinase type plasminogen activator (uPA)."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["A method of modulating cholesterol and/or lipid uptake comprising the step of administering a PAI- 1 inhibitor compound according to claim 1 in an amount effective to modulate cholesterol and/or lipid uptake."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["A method of modulating cholesterol and/or lipid clearance comprising the step of administering a plasminogen activator inhibitor-1 (PAI-1) inhibitor compound according to claim 1 in an amount effective to inhibit very low density lipoprotein (VLDL) or apolipoprotein E (ApoE) or apolipoprotein A (ApoA) binding to VLDL-R and modulate cholesterol and/or lipid clearance."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["A method of modulating cholesterol and/or lipid clearance comprising the step of administering a plasminogen activator inhibitor-1 (PAI-1) inhibitor compound according to claim 1 in an amount effective to affect HDL or apolipoprotein E (ApoE) or apolipoprotein A (ApoA) binding to an ApoA receptor and modulate cholesterol and/or lipid clearance."],"number":22,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}